The approval is great news for Human Genome Sciences, but lots of questions remain.
FORBES: Human Genome Sciences' Benlysta Approved To Treat Lupus
Wall Street expected a lupus drug Glaxo was developing with Human Genome Sciences to fail.
Doctors also presented results of competing drugs from Human Genome Sciences at the meeting.
Venter himself founded Human Genome Sciences (nasdaq: HGSI - news - people ).
This was the case of Skowron and French physician, Yves Benhamou who worked at Human Genome Sciences.
Human Genome Sciences hopes to be able to sell the drug to other friendly nations as well.
Human Genome Sciences is developing a drug, Albuferon, a combination of the human protein albumin and interferon.
Take a long, hard look at the stock chart for Human Genome Sciences since it went public in 1993.
Its collaborations with biotech firms, such as Human Genome Sciences of Maryland, have given it a springboard for future discoveries.
" Adds William Haseltine, chairman of Human Genome Sciences and an expert on viruses: "We are entering the golden age of antivirals.
For Human Genome Sciences, which does massive amounts of DNAsequencing and prepares up to 50, 000 samples a day, the cost adds up.
Adjusted for stock splits, Human Genome Sciences shares trade at one-thirtieth of what they were worth in the gene-hype-heyday of early 2000.
GlaxoSmithkline researchers discovered the gene for Lp-PLA2 a decade ago with the help of a gene database licensed from Human Genome Sciences.
McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences.
Venter, you may know, led the team that sequenced the human genome back in 2001, which was the genesis of Human Genome Sciences, Inc.
The first drugs from the genomics research of 15 years ago, from Amgen, Human Genome Sciences, and GlaxoSmithKline, are just now inching toward the market.
Human Genome Sciences ( HGSI - news - people ) was founded in the early 1990s by William Haseltine, a former Harvard researcher.
Other companies performing badly included lupus drug maker Human Genome Sciences and gout drug maker Savient Pharmaceuticals, which also faced a markedly bigger-than-expected second quarter loss.
Human Genome Sciences (nasdaq: HGSI - news - people ) is developing a drug, Albuferon, a combination of the human protein albumin and interferon.
While GSK's partner Human Genome Sciences invented the drug, Glaxo invested in HGS' gene-hunting technology back in 1993 and stayed the course even after murky early results.
Three of the more significant new positions the M100 took last week were in biotech, where they bought genome mapping company Human Genome Sciences, drug developer Biogen Idec and vaccine developer ID Biomedical.
At first he teamed up with Bill Haseltine , a virus geneticist with a record as an entrepreneur, to start an institute and a company, Human Genome Sciences, to exploit expressed sequence tags.
McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences (nasdaq: HGSI - news - people ).
What make better tests possible are gene databases, first developed in the early 1990s by Human Genome Sciences and Incyte Genomics, that categorize thousands of genes by the type of diseased tissue they inhabit.
Researchers at Genentech and Amgen, as well as at Human Genome Sciences, are in early human tests of drugs that aim to attach and stimulate so-called "death receptors" on the surface of cancer cells.
Under the leadership of genomics pioneer William Haseltine , Human Genome Sciences (nasdaq: HGSI - news - people ) has spent hundreds of millions of dollars over about a decade to develop drugs.
In the five years since Lander and Broad had their first talk, companies that aimed to make money off the genome such as Human Genome Sciences and Celera Genomics have seen their stock prices plummet by more than 80%.
Among components of that ETF with the weakest showing for the week were shares of Human Genome Sciences ( HGSI), lower by about 5.9%, and shares of Enzon Pharmaceuticals ( ENZN), lower by about 3.8% on the week.
FORBES: Banner Week For Junior Gold Miners And Regional Banks, Bad One For Biotech ETFs
应用推荐